Evidence map›Paper›PMID 25561810›Full record

Trial reportWorld journal of gastroenterology2014

Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer.

Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. circ-ZNF609: A potent circRNA in human cancers.Journal of cellular and molecular medicine · 2021
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yao-Jun YuYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Wei-Jian SunYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Ming-Dong LuYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Fei-Hai WangYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Dan-Si QiYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Yi ZhangYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Pi-Hong LiYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
He HuangYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Tao YouYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Zhi-Qiang ZhengYao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III/IV gastric cancer.

methodsA total of 53 stage III/IV gastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy. Two of the cases were excluded. The program was as follows: 75 mg/m(2) docetaxel and 85 mg/m(2) oxaliplatin on day 1 and 1500 mg/m(2) fluorouracil on days 1 to 3 for three weeks.

resultsThe tumour changes, postoperative remission rate, changes in the symptoms and adverse reactions were observed. The overall clinical efficacy (complete remission + partial remission) of the neoadjuvant chemotherapy was 62.7%. R0 radical resection was performed on 60.8% of the patients, with a remission rate (pathological complete response + pathological subtotal response + pathological partial response) of 74.2%. The Karnofksy score improved in 42 cases. The toxicity reactions mostly included myelosuppression, followed by gastrointestinal mucosal lesions, nausea, vomiting and diarrhoea.

conclusionNeoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stage III/IV gastric cancer. However, the treatment is associated with a high incidence of bone marrow suppression, which should be managed clinically.

Indexed as

GastrectomyNeoadjuvant TherapyAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDiagnostic ImagingDocetaxelDrug Administration ScheduleFemaleFluorouracilHumansKarnofsky Performance StatusMaleMiddle AgedNeoplasm StagingOrganoplatinum CompoundsDocetaxelFluorouracilOrganoplatinum CompoundsOxaliplatinTaxoidsDocetaxelGastric cancerNeoadjuvant chemotherapyOxaliplatin

Identifiers

PMID25561810
PMCPMC4277980
OpenAlexW2041000618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.